More about

Lymphoma

News
April 07, 2023
1 min read
Save

Ibrutinib indications for mantle cell, marginal zone lymphoma to be voluntarily withdrawn

Ibrutinib indications for mantle cell, marginal zone lymphoma to be voluntarily withdrawn

Janssen and Pharmacyclics intend to voluntarily withdraw the U.S. indications of ibrutinib for certain patients with lymphoma, according to a press release.

News
March 24, 2023
1 min read
Save

FDA approves leniolisib for activated phosphoinositide 3-kinase delta syndrome

FDA approves leniolisib for activated phosphoinositide 3-kinase delta syndrome

The FDA approved leniolisib as the first treatment for activated phosphoinositide 3-kinase delta syndrome in adults and pediatric patients 12 years of age and older.

News
March 21, 2023
1 min read
Save

Axicabtagene ciloleucel significantly extends survival in large B-cell lymphoma

Axicabtagene ciloleucel significantly extends survival in large B-cell lymphoma

Axicabtagene ciloleucel significantly extended survival compared with historic standard of care in a curative setting for adults with previously untreated relapsed or refractory large B-cell lymphoma, according to the agent’s manufacturer.

CME
Video

Bridging the Gap to Reach Treatment Goals in DLBCL

Bridging the Gap to Reach Treatment Goals in DLBCL
1.00 CME
1.00 NCPD
60 MINS
$0 FEE
News
March 08, 2023
2 min read
Save

FDA issues safety communication about cancers in scar tissue around breast implants

FDA issues safety communication about cancers in scar tissue around breast implants

The FDA is aware of 19 cases of squamous cell carcinoma in scar tissue that forms around breast implants, the agency announced today in a safety communication.

News
February 20, 2023
3 min read
Save

New treatment target emerges for those who relapse after CAR-T for lymphoma

New treatment target emerges for those who relapse after CAR-T for lymphoma

A novel chimeric antigen receptor T-cell therapy induced response among adults with advanced large B-cell lymphoma who relapsed after previous CAR-T, study results showed.

News
February 14, 2023
2 min read
Save

CAR T-cell recipients receive more psychological support, fear cancer progression less

CAR T-cell recipients receive more psychological support, fear cancer progression less

Patients who received chimeric antigen receptor T cells for relapsed or refractory diffuse large B-cell lymphoma feared disease progression less than those who received standard regimens, results of a cross-sectional study showed.

News
February 01, 2023
2 min read
Save

Afternoon vs. morning chemotherapy extends survival among women with lymphoma subtype

Afternoon vs. morning chemotherapy extends survival among women with lymphoma subtype

Women with diffuse large B-cell lymphoma experienced significantly longer PFS and OS when receiving chemotherapy in the afternoon compared with the morning, according to data published in JCI Insight.

News
January 26, 2023
1 min read
Save

Breyanzi study meets complete response endpoint for leukemia, lymphoma subgroup

Breyanzi study meets complete response endpoint for leukemia, lymphoma subgroup

A phase 1/phase 2 trial of lisocabtagene maraleucel for adults with advanced chronic lymphocytic leukemia or small lymphocytic lymphoma met its primary endpoint, according to the agent’s manufacturer.

News
January 26, 2023
2 min read
Save

Elderly patients with DLBCL see improved survival with at least six treatments

Elderly patients with DLBCL see improved survival with at least six treatments

NEW ORLEANS — Patients older than 80 years of age with diffuse large B-cell lymphoma more than tripled their overall survival when receiving at least six cycles of chemotherapy.

View more